Literature DB >> 18398746

Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients.

Saad Akhtar1, Amr El Weshi, Mohemmed Rahal, Yasser Khafaga, Abdelghani Tbakhi, Hind Humaidan, Irfan Maghfoor.   

Abstract

From 1996 to April 2006, 174 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin lymphoma (HL) received ESHAP as salvage and for mobilisation. Males 92, females 76. DLCL 64: HL 104, prior radiation in 35%. First relapse 45%, second relapse 12%, induction failure 43%. Median prior chemotherapy cycles were 6. Median age at apheresis was 26.5 years. Six patients failed mobilisation and 21 patients had CD34+ cells collection < 2 x 10(6)/kg on first apheresis. Median CD34+ cells/kg collection was 5.5 x 10(6)/kg for first apheresis and 6.7 x 10(6)/kg for all apheresis. We evaluated impact of histology, gender, age, stage, marrow involvement, prior radiation and chemotherapy cycles, timing (relapse1: relapse > 1: refractory), platelet count and weight. For first apheresis collection; all patients, younger age (p = 0.004), for DLCL (64), younger age (p = 0.021) and higher platelet count (p = 0.013) and for HL (104), younger age (p = 0.036) and male gender had better CD34+ cells collection. For all apheresis product, for all patients, age (p = 0.001) and no prior radiation therapy (p = 0.051) had better CD34+ cells collection. Higher first harvest CD34+ cells collection also resulted in early neutrophil (p < or = 0.001) and platelet (p = 0.004) engraftment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398746     DOI: 10.1080/10428190701843213

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

Review 1.  Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization.

Authors:  Jonathan Hoggatt; Jennifer M Speth; Louis M Pelus
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

2.  Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.

Authors:  Manuel Afable; Paolo F Caimi; Chitra Hosing; Marcos de Lima; Issa Khouri; Basem M William; Yago Nieto; Brenda W Cooper; Paolo Anderlini; Stanton L Gerson; Hillard M Lazarus; Richard Champlin; Uday Popat
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-30       Impact factor: 5.742

3.  Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.

Authors:  Andreas Humpe; Ute Buwitt-Beckmann; Natalie Schub; Martin Gramatzki; Andreas Günther
Journal:  Transfus Med Hemother       Date:  2013-07-25       Impact factor: 3.747

Review 4.  A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.

Authors:  D Sheppard; C Bredeson; L Huebsch; D Allan; J Tay
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

5.  Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.

Authors:  Yvette C Tanhehco; Jill Adamski; Mary Sell; Kathleen Cunningham; Christa Eisenmann; Deborah Magee; Edward A Stadtmauer; Una O'Doherty
Journal:  J Clin Apher       Date:  2010       Impact factor: 2.821

6.  Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.

Authors:  Ivana N Micallef; Patrick J Stiff; Edward A Stadtmauer; Brian J Bolwell; Auayporn P Nademanee; Richard T Maziarz; Angela M Partisano; Sachin Marulkar; John F DiPersio
Journal:  Am J Hematol       Date:  2013-09-09       Impact factor: 10.047

7.  Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Authors:  M E Horwitz; J P Chute; C Gasparetto; G D Long; C McDonald; A Morris; D A Rizzieri; K M Sullivan; N J Chao
Journal:  Bone Marrow Transplant       Date:  2011-11-14       Impact factor: 5.483

8.  High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.

Authors:  Muhammad Shahzad Rauf; Irfan Maghfoor; Tusneem Ahmed M Elhassan; Saad Akhtar
Journal:  Med Oncol       Date:  2014-11-28       Impact factor: 3.064

9.  Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.

Authors:  Chitra Hosing; Rima M Saliba; Sheena Ahlawat; Martin Körbling; Partow Kebriaei; Amin Alousi; Marcos De Lima; Julia-Grace Okoroji; John McMannis; Muzaffar Qazilbash; Paolo Anderlini; Sergio Giralt; Richard E Champlin; Issa Khouri; Uday Popat
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

10.  Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.

Authors:  Yuankai Shi; Ping Zhou; Xiaohong Han; Xiaohui He; Shengyu Zhou; Peng Liu; Jianliang Yang; Changgong Zhang; Lin Gui; Yan Qin; Sheng Yang; Liya Zhao; Jiarui Yao; Shuxiang Zhang
Journal:  Chin J Cancer       Date:  2015-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.